Advertisement
Canada markets open in 1 hour 47 minutes
  • S&P/TSX

    22,320.87
    +120.07 (+0.54%)
     
  • S&P 500

    5,304.72
    +36.88 (+0.70%)
     
  • DOW

    39,069.59
    +4.29 (+0.01%)
     
  • CAD/USD

    0.7323
    +0.0002 (+0.03%)
     
  • CRUDE OIL

    78.19
    +0.47 (+0.60%)
     
  • Bitcoin CAD

    93,278.14
    -1,049.15 (-1.11%)
     
  • CMC Crypto 200

    1,482.74
    -1.46 (-0.10%)
     
  • GOLD FUTURES

    2,346.60
    +12.10 (+0.52%)
     
  • RUSSELL 2000

    2,069.67
    +21.26 (+1.04%)
     
  • 10-Yr Bond

    4.4670
    -0.0080 (-0.18%)
     
  • NASDAQ futures

    18,875.25
    -0.75 (-0.00%)
     
  • VOLATILITY

    12.45
    +0.52 (+4.36%)
     
  • FTSE

    8,317.59
    -21.64 (-0.26%)
     
  • NIKKEI 225

    38,900.02
    +253.91 (+0.66%)
     
  • CAD/EUR

    0.6740
    -0.0004 (-0.06%)
     

Medivolve Announces Change of Auditor

Medivolve Inc.
Medivolve Inc.

TORONTO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Medivolve Inc. (“Medivolve” or the “Company”) (Cboe CA: MEDV; OTC: MEDVF; FRA:4NC) announces that it has changed auditors from MNP LLP (“MNP”) to MS Partners LLP (“MS Partners”), effective February 6, 2024. MNP resigned as of the effective date of January 16, 2024, and MS Partners has been appointed as the successor auditor. In accordance with National Instrument 51‐102 (“NI 51‐102”), the Company has filed a Change of Auditor Notice on SEDAR+ together with letters from both MNP and MS Partners, with each letter confirming agreement with the statements contained in the notice, as applicable. There were no reportable events (as defined in NI 51‐102) between MNP and the Company.

About Medivolve

Medivolve is a Canadian healthcare technology company headquartered in Toronto, Canada. The Company’s mission is to improve health and lives by delivering world-class diagnostic solutions—starting with COVID-19—as well as to enable faster and better care to patients through innovative technology. Medivolve, through its subsidiaries, operates retail patient-care locations in California.

For investing inquiries, please contact: David Preiner, CEO, info@medivolve.ca, 702-990-3737.